{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:59:38Z","timestamp":1761893978553},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T00:00:00Z","timestamp":1092355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Background<\/jats:title>\n                        <jats:p>Neo-adjuvant chemotherapy is an integral part of multi-modality approach in the management of locally advanced breast cancer and it is vital to predict the response in order to tailor the regime for a patient. The common final pathway in the tumor cell death is believed to be apoptosis or programmed cell death and chemotherapeutic drugs like other DNA-damaging agents act on rapidly multiplying cells including both the tumor and the normal cells by following the same common final pathway. This could account for both the toxic effects and the response. Absence or decreased apoptosis has been found to be associated with chemo resistance. The change in expression of apoptotic markers (Bcl-2 and Bax proteins) brought about by various chemotherapeutic regimens is being used to identify drug resistance in the tumor cells. A prospective clinical study was conducted to assess whether chemotherapy induced toxic effects could serve as reliable predictors of apoptosis or response to neo-adjuvant chemotherapy in patients with locally advanced breast cancer.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>50 cases of locally advanced breast cancer after complete routine and metastatic work up were subjected to trucut biopsy and the tissue evaluated immunohistochemically for apoptotic markers (bcl-2\/bax ratio). Three cycles of Neoadjuvant Chemotherapy using FAC regime (5-fluorouracil, adriamycin, cyclophosphamide) were given at three weekly intervals and patients assessed for clinical response as well as toxicity after each cycle. Modified radical mastectomy was performed in all patients three weeks after the last cycle and the specimen were re-evaluated for any change in the bcl-2\/bax ratio. The clinical response, immunohistochemical response and the drug-induced toxicity were correlated and compared.<\/jats:p>\n                        <jats:p>Descriptive studies were performed with SPSS version 10 and the significance of response was assessed using paired t-test. Significance of correlation between various variables was assessed using chi-square test and coefficient of correlation calculated by Pearson correlation coefficient.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>There was a statistically significant correlation observed between clinical, immunohistochemical response (bcl-2\/bax ratio) and the drug-induced toxicity.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusion<\/jats:title>\n                        <jats:p>Responders also had significant toxicity while non-responders did not show significant toxicity following neoadjuvant chemotherapy. The chemotherapy-induced toxicity was observed to be a cost effective and reliable predictor of response to neo-adjuvant chemotherapy.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/1471-2407-4-48","type":"journal-article","created":{"date-parts":[[2004,8,18]],"date-time":"2004-08-18T06:23:03Z","timestamp":1092810183000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer? -A prospective clinical study"],"prefix":"10.1186","volume":"4","author":[{"family":"Chintamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JP","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashima","family":"Lyall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,8,13]]},"reference":[{"key":"138_CR1","first-page":"372","volume":"40","author":"JC Paymaster","year":"1956","unstructured":"Paymaster JC: Cancer of the breast in Indian Women. Surgery. 1956, 40: 372-376.","journal-title":"Surgery"},{"key":"138_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1023\/A:1005933815809","volume":"48","author":"PA Ellis","year":"1998","unstructured":"Ellis PA, Smith IE, Detre S, Burton SA, Salter J, Hern A, Walsh G, Johnston SRD, Dowsett M: Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Research and Treatment. 1998, 48: 107-116. 10.1023\/A:1005933815809.","journal-title":"Breast Cancer Research and Treatment"},{"key":"138_CR3","doi-asserted-by":"crossref","unstructured":"Kerr JF, Winterford CM, Hormon BV: Apoptosis: its significance in cancer and cancer therapy. Cancer. 73 (8): 2013-2026. 1994 Apr 15","DOI":"10.1002\/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J"},{"key":"138_CR4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1677\/erc.0.0050199","volume":"5","author":"HA Hahm","year":"1998","unstructured":"Hahm HA, Davidson NE: Apoptosis in the mammary gland and breast cancer. Endocrine Related Cancer. 1998, 5: 199-211.","journal-title":"Endocrine Related Cancer"},{"key":"138_CR5","first-page":"231","volume":"12","author":"DJ Jussawala","year":"1978","unstructured":"Jussawala DJ, Yeole BB, Natekar MV, Narayan RA: Epidemiology of breast cancer in India. Indian J Cancer. 1978, 12: 231-242.","journal-title":"Indian J Cancer"},{"key":"138_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1023\/A:1005875002458","volume":"44","author":"A Frassoldati","year":"1997","unstructured":"Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res And Treat. 1997, 44: 185-192. 10.1023\/A:1005875002458.","journal-title":"Breast Cancer Res And Treat"},{"key":"138_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/0092-8674(93)90509-O","volume":"74","author":"ZN Oltvai","year":"1993","unstructured":"Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodermize in vivo with a conserved homologue, bax, that accelerates programmed cell death. Cell. 1993, 74: 609-615. 10.1016\/0092-8674(93)90509-O.","journal-title":"Cell"},{"key":"138_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/348334a0","volume":"348","author":"DM Hockenbery","year":"1990","unstructured":"Hockenbery DM, Nunez G, Milliman : Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990, 348: 334-336. 10.1038\/348334a0.","journal-title":"Nature"},{"key":"138_CR9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ijc.2910600622","volume":"60","author":"RC Bargou","year":"1995","unstructured":"Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995, 60: 844-859.","journal-title":"Int J Cancer"},{"key":"138_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0002-9610(97)00279-1","volume":"175","author":"A Eltahir","year":"1996","unstructured":"Eltahir A, Heys SD, Hutcheon AW, Sarkar TK, Smith I, Walker LG, Ah-See AK, Eramin O: Treatment of large and locally advanced breast cancer using neoadjuvant chemotherapy. Am J Surg. 1996, 175: 127-132. 10.1016\/S0002-9610(97)00279-1.","journal-title":"Am J Surg"},{"key":"138_CR11","first-page":"9","volume":"7","author":"G Bonadonna","year":"1988","unstructured":"Bonadonna G, Valagussa P, Zambetti M: Locally advanced breast cancer: 10 year results after combined treatment. Proceed Am Soc Clin Oncol. 1988, 7: 9-","journal-title":"Proceed Am Soc Clin Oncol"},{"key":"138_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1055-3207(18)30426-5","volume":"4","author":"A Buzdar","year":"1995","unstructured":"Buzdar A, Singletary S, Booser D: Combined modality treatment for stage III and inflammatory carcinoma of the breast. M.D. Anderson Cancer Center experience. Surg Oncol Clin North Am. 1995, 4: 715-","journal-title":"Surg Oncol Clin North Am"},{"key":"138_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/(SICI)1096-9098(199601)61:1<38::AID-JSO9>3.0.CO;2-T","volume":"61","author":"G Singh","year":"1996","unstructured":"Singh G, Singh DP, Gupta D: Neoadjuvant chemotherapy in locally advanced breast cancer. J Surg Oncol. 1996, 61: 38-41. 10.1002\/(SICI)1096-9098(199601)61:1<38::AID-JSO9>3.0.CO;2-T.","journal-title":"J Surg Oncol"},{"key":"138_CR14","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1200\/JCO.1993.11.3.467","volume":"11","author":"C Blomqvist","year":"1993","unstructured":"Blomqvist C, Elomma I, Rissanen P: Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin and flouracil in metastatic breast cancer-a randomized trial comparing weekly and every four week administration. J Clin Oncol. 1993, 11: 467-473.","journal-title":"J Clin Oncol"},{"key":"138_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/jsre.2001.6084","volume":"99","author":"GD Kymionis","year":"2001","unstructured":"Kymionis GD, Dimitrakakis CE: Can expression of apoptosis genes, bcl-2 and bax predict survival and responsiveness to chemotherapy in node negative breast cancer patients?. J Surg Res. 2001, 99: 161-168. 10.1006\/jsre.2001.6084.","journal-title":"J Surg Res"},{"key":"138_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/path.1711160302","volume":"116","author":"J Searle","year":"1975","unstructured":"Searle J, Lawson TA, Abbott PJ: An electron mocroscope study of the mode of cell death induced by cancer chemotherapeutic agents in populations of proliferating normal and neoplastic cells. J Pathol. 1975, 116: 129-138.","journal-title":"J Pathol"},{"key":"138_CR17","unstructured":"Nabusada Shinoura, Yoko Yoshida, Miyako Nishimura, Yukiko Muramatsu, Akio Asai, Takaaki Kirino, Hirofumi Hamada: Expression of BCL-2 Determines Anti- or Proapoptotic Function. Cancer Research. 59: 4119-4128. August 15 1999."},{"key":"138_CR18","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/0360-3016(79)90664-3","volume":"5","author":"P Perez","year":"1979","unstructured":"Perez P, Presant C, Philpott G: Phase I-II study of concurrent and multi drug chemotherapy in advanced carcinoma of breast: a pilot study by the south-eastern cancer study group. Int J Radiat Oncol Biol Phys. 1979, 5: 1329-","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"138_CR19","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, et al: Effect of preoperative chemotherapy of loco regional disease in women with operable cancer-Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997, 15: 2483-2493.","journal-title":"J Clin Oncol"},{"key":"138_CR20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s005950050054","volume":"30","author":"MH El-Didi","year":"2000","unstructured":"El-Didi MH, Moneer MM, Khaled HM: Pathological assessment of response of locally advanced breast cancer to neo adjuvant chemotherapy and its implication for surgical management. Surg Today. 2000, 30: 249-254. 10.1007\/s005950050054.","journal-title":"Surg Today"},{"key":"138_CR21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/ijc.2910610304","volume":"61","author":"MG Diadone","year":"1995","unstructured":"Diadone MG, Silverstrini R, Luisi A: Changes in biological markers after primary chemotherapy in breast cancers. Int J Cancer. 1995, 61: 301-305.","journal-title":"Int J Cancer"},{"key":"138_CR22","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S0093-7754(01)90132-0","volume":"28","author":"EP Mamounas","year":"2001","unstructured":"Mamounas EP, Fisher B: Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol. 2001, 28: 389-399. 10.1053\/sonc.2001.26150.","journal-title":"Semin Oncol"},{"key":"138_CR23","first-page":"132","volume":"26 A","author":"AD Thor","year":"1996","unstructured":"Thor AD, Reed JC, Sato T: Immunohistochemical analysis of bax and bcl-2 in p53 immunosuppressive breast cancers. US Canad Acad PatholAbst. 1996, 26 A: 132-135.","journal-title":"US Canad Acad PatholAbst"},{"key":"138_CR24","first-page":"5407","volume":"52","author":"T Miyashita","year":"1992","unstructured":"Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of 549.1 and WEH 17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 1992, 52: 5407-5410.","journal-title":"Cancer Res"},{"key":"138_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0074-7696(08)62312-8","volume":"68","author":"AH Wyllie","year":"1980","unstructured":"Wyllie AH, Kerr JFR, Curie AR: Cell death-the significance of apoptosis. Internat Rev Cytol. 1980, 68: 251-304.","journal-title":"Internat Rev Cytol"},{"key":"138_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H","volume":"67","author":"C Sakakura","year":"1996","unstructured":"Sakakura C, Sweeny EA, Shirahama , et al: Overexpression of bax sensitizes human breast cancer MCF-7 to radiation induced apoptosis. Int J Cancer. 1996, 67: 101-105. 10.1002\/(SICI)1097-0215(19960703)67:1<101::AID-IJC17>3.0.CO;2-H.","journal-title":"Int J Cancer"},{"key":"138_CR27","first-page":"1323","volume":"145","author":"S Krajewski","year":"1994","unstructured":"Krajewski S, Krajewska M, Shabaik A: Immunohistochemical determination of bax a dominant inhibitor of bcl-2. Amer J Pathol. 1994, 145: 1323-1336.","journal-title":"Amer J Pathol"},{"key":"138_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1023\/A:1021119830269","volume":"77","author":"F Feuerhake","year":"2003","unstructured":"Feuerhake F, Sigg W, Hofter EA: Cell proliferation, apoptosis and expression of bcl-2 and bax in non lactating human breast epithelium in relation to the menstrual cycle and reproductive history. Breast Cancer Res Treat. 2003, 77: 37-48. 10.1023\/A:1021119830269.","journal-title":"Breast Cancer Res Treat"},{"key":"138_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/bjc.1994.303","volume":"70","author":"SA Rasbridge","year":"1994","unstructured":"Rasbridge SA, Gillett CE, Seymour AM: The effect of chemotherapy on morphology, cellular proliferation, apoptosis oncoprotein expression in primary breast carcinoma. Br J Cancer. 1994, 70: 335-341.","journal-title":"Br J Cancer"},{"key":"138_CR30","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxyrubicin based neoadjuvant chemotherapy. J Clin Oncol. 1999, 17: 460-469.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-4-48\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-4-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T12:34:12Z","timestamp":1728304452000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-4-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,13]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,12]]}},"alternative-id":["138"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-4-48","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2004,8,13]]},"assertion":[{"value":"1 December 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2004","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2004","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"48"}}